cyrilzakka/clinical-trials huggingface dataset:
A Combined Surgical and Medical Approach in Mild Sleep Apnea

The aim of the study is to investigate wether the adjuvant (postoperative) administration of acetazolamide can improve the surgical results after uvulopalatopharyngoplasty in patients with mild sleep apnea.


Eligibility Criteria:
Inclusion Criteria:

* 5 ≤ Apnea Hypopnea Index (AHI) \< 20
* Socially disturbing snoring: Visual Analogue Scale (VAS)snoring \> 6/10
* Based on clinical examination and polysomnography, patient is regarded eligible for uvulopalatopharyngoplasty (UPPP)

Exclusion Criteria:

* Previous surgical treatment for sleep-disordered breathing.
* Periodic Limb Movement Disorder (PLMD) with arousals and other reasons possibly explaining the Excessive Daytime Sleepiness (EDS) based on Epworth Sleepiness Scale (ESS).
* Forced expiratory volume in 1 second (FEV1) \< 80 % pred.
* Echocardiography: ejectionfraction \< 35 % or dyastolic dysfunction grade 2 or more.
The Effect of Chocolate on Vascular Function of Endurance Runners

The aim of this study is to examine the effects of chocolate on the vascular function of endurance runners through a crossover study involving male runners consuming both dark and white chocolate.

Participants will be male endurance runners who will receive both black and white chocolate interventions. Arterial stiffness, cardiovascular parameters, respiratory parameters, and running performance will be assessed before and after each intervention period. The study will involve a two-week intervention period for each type of chocolate, with a washout period in between. The primary outcome measure will be arterial stiffness, while secondary outcome measures will include cardiovascular and respiratory parameters, as well as running performance. The study is expected to provide insights into the effects of chocolate consumption on vascular function in endurance athletes.

Eligibility Criteria:
Inclusion Criteria:

* Gender: Male
* Age: 25-55 years
* Healthy status
* Active endurance runner
* Regular physical activity (at least 3 times per week)
* Availability on specific days and times for research sessions
* Willingness and consistency

Exclusion Criteria:

* Allergies or Intolerances: Participants with known allergies or intolerances to chocolate or any of its ingredients.
* Cardiovascular Diseases: Participants with known cardiovascular diseases or history of cardiac episodes.
* Metabolic Disorders: Individuals with diabetes or other metabolic disorders that may affect glucose and insulin metabolism.
* Contradictory Diet: Individuals following specific diets that may affect the study, such as high or low flavonoid diets.
* Medication Use: Individuals taking medications that affect vascular function, such as antihypertensives or anticoagulants.
* Smoking: Smokers or individuals who have quit smoking within the last six months.
* Substance Abuse: Individuals with a history of alcohol or substance abuse.
* Patients with Chronic Diseases: Individuals with serious chronic diseases that may affect the study outcomes.
* Participation in Other Studies: Individuals participating in other clinical trials or research that may affect the study outcomes.
* Physical Condition: Individuals who are not regular runners or who do not exercise regularly at a level similar to other participants.
International Multicentric Observational Study to Characterize Subpopulations of Patients with Autism Spectrum Disorder

To determine sufficient number of biological and clinical markers to identify subgroups of potential best responders to a specific medication


Eligibility Criteria:
Inclusion Criteria:

* Participants previously diagnosed with ASD (DSM-5)
* Available well-documented health records within the first 2 years of life
* Participants must have a parent or reliable caregiver who agrees to provide information about the participant
* Participants willing and consenting or assenting to participate.

Exclusion Criteria:

* Episode of fever (i.e. ≥100.5 °F or ≥ 38 °C) or clinically significant illness without fever (as judged by the investigator), within 10 days before any study assessment.
* If the investigator assesses any unwillingness or any medical condition that may prevent the subject from completing this study.
Patient Perspectives in Squamous Cell Carcinoma Clinical Trials

Clinical research participation has historically been heavily biased toward specific demographics.

This study will invite several participants to gather a wide range of information on clinical trial experiences for squamous cell carcinoma patients. The aim of the study is to identify the factors that limit the ability of a person to enroll in, as well as complete a clinical trial for treatment of squamous cell carcinoma.

People with squamous cell carcinoma who are invited to take part in clinical research will benefit from the analysis of the data.


Eligibility Criteria:
Inclusion Criteria:

* Aged ≥ 18 years old
* Confirmed diagnosis of squamous cell carcinoma
* Subjects willing and able to comply with the protocol for the duration of the study including undergoing treatment and scheduled visits and examination.

Exclusion Criteria:

* Inability to provide written informed consent
* Is pregnant, breastfeeding or expecting to conceive within the projected duration of the study
* Enrolled in another research study
Treatment of Surgical Scars Following Breast Augmentation, Abdominoplasty or Face Lift

Evaluator-blinded study of the safety and performance of fractional radiofrequency (FRF) for the treatment of surgical scars following breast augmentation, abdominoplasty or facelift. The study will enroll up to 50 female subjects requesting treatment of surgical scars following breast augmentation or abdominoplasty and up to 25 male and female subjects requesting treatment of surgical scars following facelift surgery. Subjects will receive a total of 3 treatments of their surgical scars at 1-month intervals. Subjects will be followed up at 10 months after their last treatment (12 months after the first treatment).


Eligibility Criteria:
Inclusion Criteria:

1. Healthy, female, subjects 20-60 years of age who are seeking treatment for their breast augmentation or abdominoplasty surgical scars or male and female patients 40-75 years of age who are seeking treatment for their face lift surgical scars.
2. A minimum of four weeks since surgery.
3. Able to read, understand and voluntarily provide written Informed Consent.
4. Able and willing to comply with the treatment/follow-up schedule and requirements.
5. Willing to avoid direct sunlight for the duration of the study.
6. Women of child-bearing age are required to be using a reliable method of birth control at least 3 months prior to study enrollment and for the duration of the study, and have a negative Urine Pregnancy test at baseline.

Exclusion Criteria:

* 1. Fitzpatrick skin types 5-6. 2. Implantable defibrillators, cardiac pacemakers, and other metal implants 3. Subjects with any implantable metal device in the treatment area 4. Pacemaker or internal defibrillator, or any other active electrical implant anywhere in the body (e.g. cochlear implant).

  5. Permanent implant in the treated area, such as metal plates and screws, or an injected chemical substance.

  6. Current or history of any kind of cancer, or pre-malignant moles. 7. Severe concurrent conditions, such as cardiac disorders. 8. Pregnancy or intending to become pregnant during the study and nursing. 9. Impaired immune system due to immunosuppressive diseases, such as AIDS and HIV, or use of immunosuppressive medications.

  10. History of diseases stimulated by heat, such as recurrent herpes simplex in the treatment area; may be enrolled only following a prophylactic regime.

  11. Poorly controlled endocrine disorders, such as diabetes. 12. Any active condition in the treatment area, such as sores, psoriasis, eczema, and rash.

  13. History of skin disorders, such as keloids, abnormal wound healing, as well as very dry and fragile skin.

  14. History of bleeding coagulopathies, or use of anticoagulants. 15. Use of isotretinoin (Accutane®) within six months prior to treatment. 16. Treating over tattoo or permanent makeup. 17. Excessively tanned skin from sun, tanning beds or tanning creams within the last two weeks.

  18. As per the practitioner's discretion, refrain from treating any condition which might make it unsafe for the patient.
Guided Self-Help for Parents of Adolescents With Attention-Deficit/Hyperactivity Disorder (ADHD)

Cognitive-behavioral based guided self-help for parents of adolescents with Attention-Deficit/Hyperactivity Disorder (ADHD) is investigated in a feasibility and effectiveness study. The treatment is offered under routine-care conditions of the health-care system in Germany. Practicability, treatment participation and effectiveness is documented and tested in a one-group pre-test/post-test design.

Self-directed interventions may overcome many of the barriers associated with accessing face-to-face services, as there is lowered stigma and significantly reduced or eliminated cost, transport, and timing difficulties. Families can complete self-directed programs at home, in their own time and at their own pace. Furthermore self-administered programs are often very cost-effective and their use can ease the financial burden of mental health of the community. These parenting programs can be particularly effective by reaching the populace. Moreover in primary care settings where financial resources, time and expertise might be lacking to provide behavioral interventions, self-directed programs might be a promising tool for disseminating effective parenting interventions more widely.

Bibliotherapy is one form of self-directed therapy. In bibliotherapy a selected book is thought to meet the specific need of the person to be treated and reading is used as the therapeutic technique. In opposition to pure self-help programs, bibliotherapy in terms of guided self-help provides patients (or parents) with written instructions as well as therapeutic contacts at regular intervals. During these contacts, problems and questions can be discussed to give further support. Self-help interventions have already proven to be effective for adults with anxiety or affective disorders as well as for depressive adolescents. However there has only been little research concerning the reduction of children's and adolescent´s behaviour problems through parental self-help programs under minimal contact conditions.

Eligibility Criteria:
Inclusion Criteria:

* Adolescent with a diagnosis of ADHD

Exclusion Criteria:

* Language or reading difficulties of participating parent
Intercostal Nerve Block With Local Anesthesia Administered Via Incision-specific Multi-site Injection for Thoracic Surgery

The goal of this clinical trial is to test analgesic effect of intercostal nerve block in different range. The main question it aims to answer are:

question 1: whther incision-specific multi-site injection (ISMSI, from the 3rd to 8th intercostal nerve) can improve the analgesic benefits .

The participants will be divided into three groups to compare the analgesic effects of different intercostal nerve blocks

Postoperative pain after thoracic surgery is usually severe, and potentially leads to worse outcomes. It is well known that the use of intercostal nerve block (ICNB) analgesia with local anesthesia is common in thoracic surgery. Compared with the traditional standard of epidural analgesia, it has the advantages of less effect on respiratory or circulation system and less postoperative complications such as hypotension and hematoma. However, the details of ICNB form different hospital are in different ways. And it is unclear how many intercostal nerves should be blocked. And it is unknown which area should be payed more attention either, like the incision area or the chest tube port. It is hypothesized that the incision-specific multi-site injection (ISMSI, from the 3rd to 8th intercostal nerve) can improve the analgesic benefits due to cover area of both incision and chest tube port. To test this hypothesis, the investigators did this study to evaluate the analgesic effect of different ICNB methods.

The participants will be divided into three groups. A(incision-specific multi-site injection, received intraoperative 3-8 intercostal nerve block ) B(single injection, received intraoperative 3-5 intercostal nerve block ) and C(received no intercostal nerve block). Then compare the analgesic effects of the three groups.

Eligibility Criteria:
Inclusion Criteria:

1. Patients undergoing surgery for small pulmonary nodules in the Department of Thoracic Surgery, China-Japan Friendship Hospital in Beijing
2. Age≥ 18 years old
3. Lung small nodules with a diameter of ≤ 2cm, pure ground-glass/mixed/solid nodules
4. Permanent residents can be followed up for a long time
5. Sign informed consent.

Exclusion Criteria:

1. Refusal to sign informed consent
2. Damaged heart, lung, liver and kidney function
3. Contraindications to surgery, such as inability to tolerate anesthesia, distant metastasis, bleeding tendency, etc c(4) Combined with severe emphysema, tuberculosis, pneumothorax, pleural effusion (5) Patients have other conditions that are not suitable for interventional surgery, such as pregnancy, lactation, long-term use of immunosuppressants, and serious infections
Comparison of Radiological, Clinical, Functional Outcomes Between Anatomically Aligned Total Knee Arthroplasty and Conventional Total Knee Arthroplasty

Total knee arthroplasty(TKA) is a successful orthopedic surgery with excellent clinical outcome and survival. However, there are concerns about patient satisfaction in previous reports, and dissatisfaction rate of 15-30% is reported in clinical outcomes(PROMs) of some studies. Therefore, for improving the patient's outcome and satisfaction after total knee arthroplasty, it is necessary to change the design of the conventional total knee arthroplsaty implant. The knee is a joint structure with several dynamic functions, and not only the skeletal structure but also the soft tissue balance plays an important role in the function of the knee joint. New implants are being developed to overcome the limitations of conventional TKA implant, including the Journey II Bi-cruciate substituting total knee system (JII-BCS; Smith \& Nephew). JII-BCS implant has normal articular geometry, more anatomical femoral shape, lateral tibial convex geometry, and asymmetrical tibial plateau, anterior and posterior cams, which has been shown in experimental studies to produce nearly normal knee movement by reproducing the actual normal anatomical alignment in vivo.

The clinical results of the kinematic effects of this anatomcally aligned change are insufficient, and there is also a lack of comparative studies with conventional total knee arthroplasty implant. The purpose of this study is to compare outcomes between anatomically aligned TKA(JII-BCS) and conventional TKA(Legion total knee system, Smith \& Nephew). This study is a randomized controlled study in patients undergoing same-day bilateral total knee arthroplasty. A patient undergoing same-day bilateral total knee arthroplasty will use a random number to determine the instruments(JII-BCS or Legion), and both knee joints will be operated with the same instruments. Radiologic parameter, patients preference and clinical results was investigated in patients who received TKA during minimum 2 year follow up.


Eligibility Criteria:
Inclusion Criteria:

* Patients for bilateral total knee arthroplasty
* having medicare insurance

Exclusion Criteria:

* Rheumatoid arthritis
* Other inflammatory arthritis
* Crystal-induced arthritis
* Septic arthritis
* Neuropsychiatric patients
* Previous knee operation history
* Neuropsychiatric patients
* Patients with preoperative severe limitation of motion (Flexion contracture ≥ 20, range of motion ≤ 90)
* Patients with preoperative severe defomity of knee alignment (Varus or valgus angle ≥ 15)
* Severe obese patients (BMI ≥ 40)
Scientific Research Barriers by Gender and Other Characteristics in Physiatry

The ever-increasing population and life expectancy worldwide lead to a higher prevalence of physical disabilities and diseases, which increases the need for physical medicine and rehabilitation research. In our study, we aimed to evaluate various aspects of the barriers, particularly gender disparities, faced by physical medicine and rehabilitation professionals who wish to conduct scientific research.

Physicians in physical medicine and rehabilitation must also put in tremendous effort and manage their time meticulously to contribute to scientific research (SR). Research requires knowledge, experience, and institutional support, such as financial incentives, technical facilities, and trained personnel. In this field, research productivity is increasingly important due to the rising prevalence of conditions such as age-related disability and chronic pain, which put pressure on the healthcare system and affect people's quality of life. Turkey's publication productivity in physical medicine and rehabilitation has also increased steadily in recent years, with a significant number of articles published between 2015 and 2020. However, gender disparities in academic leadership positions persist in this field as well, with women lagging behind men in the number of scientific publications. While bibliometric studies are useful for assessing the current state of scientific performance, survey studies are necessary to identify obstacles that deter researchers and increase research productivity. Unfortunately, few studies have used this approach in physical medicine and rehabilitation, and no such study has been conducted in Turkey.

Eligibility Criteria:
Inclusion Criteria:

* Being a physical medicine and rehabilitation physician.
* Giving consent to participate in the study.

Exclusion Criteria:

- Not giving consent to participate in the study.
Oral Arsenic Trioxide for Newly Diagnosed Acute Promyelocytic Leukaemia

Acute promyelocytic leukemia (APL) is characterized by t(15;17)(q24;21) and the fusion gene PML-RARA. We have formulated an oral preparation of As2O3 (oral-As2O3), and shown that it is efficacious for APL in R1, inducing CR2 in more than 90% of patients. Furthermore, in an effort to prevent relapse, we have moved oral-As2O3 forward to the maintenance of CR1. This strategy results in favorable overall-survival (OS) and leukemia-free-survival (LFS), implying that prolonged treatment with oral-As2O3 may prevent relapses. Current protocols have incorporated i.v.-As2O3 in the treatment of newly-diagnosed APL. In regimens comprising i.v.-As2O3, ATRA and chemotherapy, 5-year overall survivals in excess of 90% is achieved. In this study, we evaluate the use of oral-As2O3 and ATRA based induction regimens in newly diagnosed patients with APL. In this study, we evaluate the efficacy and tolerability of frontline oral arsenic trioxide-based regimen in newly diagnosed patients with acute promyelocytic leukaemia


Eligibility Criteria:
Inclusion Criteria:

* Newly diagnosed patients with acute promyelocytic leukaemia (APL) with t(15;17) (q24;q21)according to the World Health Organization (WHO) Classification 2016
* Patients aged ≥18 years
* Able and willing to comply with the study procedures and restrictions
* Having given voluntary written informed consent

Exclusion Criteria:

* ECOG performance status above 2
* Decompensated heart failure with left-ventricular ejection fraction of less than 40% and global hypokinesia on echocardiogram.
* Prolonged corrected QT interval (QTc) \> 500ms, in the absence of electrolyte disturbances and medications known to prolong QTc
* Significant liver function derangement (Bilirubin \> 3 times upper limit normal and/or ALT \> 5 times upper limit of normal)
* Acute myeloid leukaemia with variant RARA translocation
ATG Plus Low-dose PT-Cy for GVHD Prevention

During the past decades, the wider application of easily available haploidentical donor hematopoietic cell transplant (haplo-HCT) has been made possible through the T cell-replete (TCR) regimens including T cell regulation with anti-thymocyte globulin (ATG)/granulocyte colony-stimulating factor (GCSF) and post-transplant cyclophosphamide (PTCy). To achieve decreased non-relapse mortality (NRM) and improved long-term outcomes in haploidentical transplant, the joint use of ATG and PTCy might effectively reduce graft versus host disease (GVHD) and mortality associated with severe forms of GVHD. Recently, investigators established a regimen using low-dose PTCy in conjunction with standard-dose ATG in order to lower the risk of GVHD without compromising engraftment and disease relapse.


Eligibility Criteria:
Inclusion Criteria:

1. Patients with acute leukemia and/or myelodysplastic syndrome undergoing their first allogeneic hematopoietic stem cell transplantation;
2. Male or female , aged 12-55 years;
3. Haploidentical donor transplantation;
4. ECOG score ≤3; The basic organ function tests met the following standards;

1) Cardiac ejection index \>55% 2) Creatinine ≤1.5 times the highest normal value (ULN)

Exclusion Criteria:

1. Severe brain, heart, kidney or liver dysfunction;
2. Refractory malignant state;
3. Patients with other malignant tumors requiring treatment;
4. Clinically uncontrolled severe active infection;
5. The expected survival time was less than 3 months.
6. A history of severe anaphylaxis.
7. Pregnant or lactating women;
8. Any condition considered by the investigators to be unsuitable for enrollment.